Current Report Filing (8-k)
June 22 2023 - 6:01AM
Edgar (US Regulatory)
0001442999
false
0001442999
2023-06-14
2023-06-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): June 14,
2023
Alterola Biotech, Inc.
(Exact name of registrant as specified in its charter)
| Nevada |
333-156091 |
82-1317032 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
47 Hamilton Square Birkenhead Merseyside United
Kingdom |
CH41 5AR |
| (Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including area code: +44 151 601
9477
|
________________________________________________
(Former name or former address, if changed since last
report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] |
Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) |
| |
|
| [ ] |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| [ ] |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| [ ] |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. [ ]
Section 5 - Corporate Governance
and Management
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 14, 2023, the following Directors were issued the following amounts
of ABTI common stock as payment for their services as Directors.
Mr. Dewi David Hitchcock (4,000,000 shares)
Partner Investments B.V. (beneficial owner = Dr. Ning Qu) (2,000,000 shares)
Dr. Daniel Reshef (2,000,000 shares)
Dr. Michael Hunter Land (1,000,000 shares)
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Alterola Biotech, Inc.
/s/ David Hitchcock
David Hitchcock
Chief Executive Officer
Date: June 21, 2023
Alterola Biotech (PK) (USOTC:ABTI)
Historical Stock Chart
From Oct 2024 to Nov 2024
Alterola Biotech (PK) (USOTC:ABTI)
Historical Stock Chart
From Nov 2023 to Nov 2024
